Topics

Ocular Therapeutix, Inc. Settles Litigation with Mati Therapeutics, Inc.

08:00 EDT 30 Apr 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has settle...

Other Sources for this Article

Investors
Ocular Therapeutix
Donald Notman
Chief Financial Officer
dnotman@ocutx.com

or

Westwicke, an ICR Company
Chris Brinzey, 339-970-2843
Managing Director
chris.brinzey@westwicke.com

Media
Ocular Therapeutix
Scott Corning
Senior Vice President, Commercial
scorning@ocutx.com

NEXT ARTICLE

More From BioPortfolio on "Ocular Therapeutix, Inc. Settles Litigation with Mati Therapeutics, Inc."

Quick Search

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...